Company

Menarini

As of the edition of 20 October 2026, Menarini runs 8 drugs; it is on route A at 3 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

StatusCount
Active2
Went quiet2
Stopped3
Status not established1
Total8

Where it needs a new molecule

Route A at 3 targets, route B at 0 targets.

Three of its 3 rows, by target and route
TargetRoute
TACR2 Substance-K receptorRoute A
BDKRB2 B2 bradykinin receptorRoute A
MUC16 Mucin-16Route A

All 3 rows on route A or B

In the product

3 company-target rows on route A or B; 0 are not shown here, and no score is.

Where its trials are

  • Digestive system: 7 trials led
  • Cancer: 6 trials led
  • Inherited and neonatal: 4 trials led